Ondansetron exhibits potent antiviral activity against enterovirus 71 infection in vitro and in vivo Authors: Zhenyang Li, Jianqiao Rui, Jiazheng Li, Sichen Ren, Yan Luo, Weiyan Zhu, Huimin Tao, Mingzhu Guo, Qingsong Dai, Wan Peng, Siqi Li, Xiaojia Guo, Wei Li, Jingjing Yang, Ruiyuan Cao, Wu Zhong Published: 2026 ABSTRACT Highlights•Ondansetron inhibits EV-A71 infection in vitro and in vivo.•Ondansetron acts at the early stage of viral attachment and entry.•Cholesterol metabolism genes (ABCA1, ABCG1, HMGCS1) are modulated.•Targeting host lipid homeostasis represents a novel antiviral strategy. Introduction Enterovirus A71 (EV-A71) is a non-enveloped enterovirus of the family Picornaviridae, comprising a positive-sense single-stranded RNA genome of approximately 7.4 kb encapsulated within an ∼30 nm icosahedral capsid composed of VP1-VP4 (Baggen et al., 2018; Huang et al., 2019; Kinobe et al., 2022). EV-A71 is one of the major etiological agents of hand, foot, and mouth disease (HFMD). Clinical manifestations range from mild symptoms such as fever and vesicular lesions on the hands and feet to severe complications including brainstem encephalitis, acute flaccid paralysis, and cardiopulmonary failure. Severe pediatric cases have poor outcomes and high mortality (Chang et al., 2019; Teoh et al., 2016; Hsia et al., 2020). Studies have identified SCARB2 as a primary receptor mediating EV-A71 entry, and the naturally high expression of SCARB2 on neurons and glial cells provides a prerequisite for central nervous system (CNS) infection (Yamayoshi et al., 2009; Yamayoshi et al., 2014; Nishimura et al., 2009). EV-A71 can invade the CNS via multiple routes: retrograde axonal transport, disruption of the blood-brain barrier (BBB), and immune cell-mediated translocation across the blood-brain barrier (Chen et al., 2007; Wang and Liu, 2009; Fujii et al., 2013). Moreover, because the immune system of children is not yet fully mature and the nervous system is still developing, their resistance to viral infection is relatively weak, and CNS involvement often leads to severe consequences. At present, there are no approved specific antiviral drugs for EV-A71 infection in the clinic. Only vaccines are available for prevention (Wang et al., 2024; Wang et al., 2022; Lin et al., 2019; Yang et al., 2017). Therefore, screening and identifying therapeutics for EV-A71 infection have the important clinical significance. Given the stringent safety requirements for pediatric drug approvals, drug repurposing-screening and evaluating already marketed drugs-represents an important strategy for developing new treatments. Previous studies have found that 65.5% of severe EV-A71 patients show abnormal signals in the brainstem on MRI, primarily localized in the raphe nucleus group, which contains a high density of 5-HT neurons. Further research has shown that EV-A71 infection can promote excessive abnormal secretion of 5-HT and, by acting on serotonin receptors, lead to alterations in consciousness, delirium, increased muscle tone, and muscle spasms in patients (Zhu et al., 2022; Hoyer et al., 2002). Serotonin receptors constitute a receptor family for which 5-hydroxytryptamine (5-HT) serves as the endogenous ligand. These receptors are widely distributed in both the central and peripheral nervous systems, particularly abundant in the gastrointestinal system in the periphery. Based on their molecular subtypes, they can be classified into seven types (5-HT1–5-HT7), among which the 5-HT3 receptor is a ligand-gated ion channel, while the others are G protein-coupled receptors (Kitson, 2007; Hannon and Hoyer, 2008; Hagbom et al., 2017). On light of these findings, we propose that 5-HT and its receptors may play a critical role in the disease progression of EV-A71 infection. Ondansetron is a highly selective and potent 5-HT3 receptor antagonist, clinically used primarily to treat vomiting associated with chemotherapy, radiotherapy, surgical anesthesia, and acute gastroenteritis. Previous studies have found that ondansetron can alleviate clinical symptoms and promote recovery in patients infected with rotavirus and norovirus, suggesting that it may also possess certain antiviral effects (Li et al., 2014). However, its role in antiviral research remains unclear, and no studies have reported on this to date. Considering this background, we became highly interested in whether ondansetron could exert effects against EV-A71 infection. Through both in vitro and in vivo experiments, we indeed found that ondansetron exhibits a clear inhibitory effect on EV-A71 infection. Materials and methods Cells, viruses, and reagents Human rhabdomyosarcoma (RD) cells (ATCC CCL-136) and SK-N-SH cell lines (ATCC HTB-11) were maintained in Dulbecco's Modified Eagle Medium (DMEM; Gibco 2367,374) supplemented with 10% fetal bovine serum (FBS; Gibco 1807,622) and 1% penicillin/streptomycin (PS; Gibco 2321,152) under 5% CO₂ at 37 °C. The EV-A71 H strain (ATCC VR-1432) and immunological reagents were obtained from the following sources: mouse anti-EV-A71 VP1 monoclonal antibody (12D7) from Professor Tong Cheng's laboratory (Hao et al., 2019). anti-α-tubulin antibody (Abcam ab7291), HRP-conjugated goat anti-mouse IgG (Abcam ab205719), Goat anti-Mouse IgG (H+L) Secondary Antibody, FITC (ThermoFisher, A16067), and Hoechst 33,342 nuclear stain (Invitrogen H21492). Pharmacological agents included ondansetron hydrochloride (TargetMol T6616), and NITD008 (MCE HY-12,957). HTR3A Polyclonal antibody (29,685-1-AP) was from Proteintech. Granisetron (HY-B0071), Tropisetron (HY-B0072), and Palonosetron (HY-A0018) are from MCE. All compounds were dissolved in DMSO to 100 mM stock concentrations and stored at −20 °C for in vitro studies. For in vivo administration, ondansetron was prepared in saline. Antiviral activity assay Antiviral evaluation was conducted in 96-well plates per established protocols (Li et al., 2022). RD cells (1.5 × 10⁴ cells/well) were seeded in white-walled clear-bottom plates and cultured for 24 h prior to infection. Test compounds (ondansetron) underwent 3-fold serial dilution (100–0.01 μM) in DMEM containing 2% FBS, with DMSO-treated wells as controls. EV-A71 inoculum (100 TCID₅₀ in 2% FBS DMEM) was introduced to compound-pretreated cells. Following 72 h incubation at 37 °C, cell viability was determined using the CellTiter-Glo assay (Promega, G7570) according to manufacturer specifications, with luminescence quantification via SpectraMax M5 microplate reader (Molecular Devices). Dose-response curves and EC₅₀ values were generated using Origin 9.0. Viral suppression was further investigated through plaque formation units (PFU) and qRT-PCR quantification. RD cells (4 × 10⁵ cells/well in 12-well plates) were infected with EV-A71 (MOI=0.001) in compound-containing medium. Supernatant virion production and intracellular viral RNA levels were assessed at 36hpi using plaque assays and SYBR Green-based RT-PCR respectively. Immunofluorescence assay RD cells (1.5 × 10⁴ cells/well) were cultured in 96-well plates for 24 h prior to EV-A71 H strain infection (MOI=0.001) with compound co-treatment. Following 48 h incubation, cells were fixed with 4% paraformaldehyde (30 min, RT), permeabilized with 0.1% Triton X-100 (30 min, RT), and blocked with 5% BSA (30 min, 37 °C). Sequential incubations were performed with mouse anti-VP1 antibody (12D7; 1:5000, 37 °C, 1 h) and Goat anti-Mouse IgG (H+L) Secondary Antibody, FITC (ThermoFisher, A16067) (1:500, 37 °C, 1 h). Nuclei were counterstained with Hoechst 33,342 (30 min, RT) after thrice-washed PBS steps. Fluorescent images were acquired using a Leica DMi8 inverted microscope. Amplex Red Cholesterol and Cholesteryl Ester Assay Kit (S0211S) is from Beyotime. Time-of-drug-addition assay The temporal drug efficacy was evaluated as previously established (Deng et al., 2014). RD cells (4 × 10⁵ cells/well) were seeded in 12-well plates and cultured overnight. Following EV-A71 H infection (MOI=0.001), cells received ondansetron (30 μM) or NITD008 (1 μM) according to predefined treatment schedules. Total RNA was extracted at 12hpi for subsequent qRT-PCR analysis of viral replication dynamics. Quantitative real-time PCR Total RNA was extracted using the RNeasy Mini Kit (Qiagen, Cat. 74,106). EV-A71 RNA levels were quantified by one-step qRT-PCR (One Step PrimeScript RT-PCR Kit, Takara, Cat. RR064A) with virus-specific primers (Forward: 5′-CCAATCTCAGCGGCTTGGAG-3′; Reverse: 5′-CACTCAAGCTCTACCGGCAC-3′) and a dual-labeled probe (FAM-TCCAATCGATGGCTGC -TCACCTGCGT-BHQ1). Absolute RNA copy numbers were determined by linear regression of Ct values against a standard curve generated from serial dilutions of plasmid controls. Relative quantitative PCR (RT-qPCR) was performed in triplicate qPCR reactions for both target and reference genes (ABCA1: Forward 5′-GGAAGAACAGTCATTGGGACAC-3′; Reverse: 5′-GCTACAAA-CCCTTTTAGCCAGT-3′; ABCG1: Forward 5′- ATTCAGGGACCTTTCCTATTCGG-3′; Reverse: 5′- CTCACCACTATTGAACTTCCCG-3′; HMGCS1: Forward 5′- GATGTGGGAATTGTTGCC -CTT-3′; Reverse: 5′-ATTGTCTCTGTTCCAACTTCCAG-3′; GAPDH Forward 5′- GGAGCGAGATCCCTCCAAAAT-3′; Reverse: 5′- GGCTGTTGTCATACTTCTCATGG −3′;) and calculated by using the 2−ΔΔCt method. Western blot assay RD cells were seeded in 12-well plates (4.0 × 10⁵ cells/well) and cultured overnight. Cells were subsequently infected with EV-A71 (MOI=0.001) in 2% FBS DMEM containing serially diluted compounds: ondansetron (30–0.37 μM). Control groups received virus- and compound-free 2% FBS DMEM. Following 36 h incubation, cells were washed thrice with ice-cold PBS and lysed in 150 μL RIPA buffer supplemented with protease/phosphatase inhibitors. Protein lysates were resolved through 10% SDS-PAGE and electro transferred onto PVDF membranes. Membranes were sequentially blocked with 5% non-fat milk (1 h, RT), probed overnight at 4 °C with anti-VP1 (1:1000) or α-tubulin (1:5000) antibodies, and incubated with HRP-conjugated goat anti-mouse IgG (1:5000, 1 h, RT). Chemiluminescent signals were captured using a FluorChem imaging system (ProteinSimple). EV-A71 infection in mice Neonatal ICR mice (1-day-old; Vital River Laboratory, Beijing) were intraperitoneally inoculated with EV-A71 H strain (10⁶ PFU/mouse) in 25 μL volume. At 4 h post-infection (hpi), treatment groups received daily intraperitoneal injections for 7 consecutive days: ondansetron (1.5, 0.75, 0.37mg/kg). Virus controls received equivalent saline injections. Body weights and survival rates were monitored through 21 days post-infection (dpi), with survival analysis performed using Mantel-Cox log-rank test. Clinical symptoms were scored as follows: 0, healthy; 1, ruffled fur and hunchbacked appearance; 2, weakness in the hind limbs; 3, paralysis in a single hind limb; 4, paralysis in both hind limbs; 5, moribundity and death. Four experimental groups (n = 10/group) received pre-exposure prophylaxis: ondansetron (1.5 mg/kg), or 0.5% CMCNa vehicle, administered every 12 h for 72 h prior to EV-A71 challenge (10⁵ PFU/mouse). At 24 h post-challenge, mice were euthanized for tissue collection (brain, hind limp muscle, liver, lung, spleen). Viral RNA quantification was performed via absolute qRT-PCR using tissue homogenates. Transcriptome analysis RD cells were treated with Ondansetron (0.1% DMSO control) and EV-A71 (MOI=0.001) in 2% FBS DMEM with 1% penicillin-streptomycin at 37 °C for 24 h. Total RNA was isolated using TRIzol (Invitrogen), with purity verified by NanoDrop One spectrophotometry. RNA sequencing libraries were prepared and sequenced by Majorbio Biotech (Shanghai) on the Illumina platform. Bioinformatics analysis was conducted via the Majorbio Cloud Platform (www.majorbio.com; accessed 2024–08–20). Statistical analysis Statistical analyses were performed using GraphPad Prism 7.0. Survival curves were compared by Mantel-Cox log-rank test. Intergroup differences were assessed using unpaired two-tailed Student's t-test (two groups) or one-way ANOVA (multiple groups). Statistical significance was defined as p < 0.05. Results Ondansetron inhibits EV-A71 infection in vitro To assess the antiviral efficacy of ondansetron against EV-A71, a cytopathic effect (CPE) protection assay was conducted in rhabdomyosarcoma (RD) cells. The results demonstrated that ondansetron show the dose-dependent protective effects against EV-A71-induced CPE. The half-maximal effective concentrations (EC₅₀) for these compounds were determined as follows: ondansetron (2.02 ± 1.42 μM) (Fig. 1B). Notably, ondansetron also exhibited minimal cytotoxicity, with half-maximal cytotoxic concentrations (CC₅₀) exceeding 100 μM. Corresponding selectivity index (SI) values in RD cells were calculated as >48.63 for ondansetron (Figs. 1B). These data collectively indicate that ondansetron exerts significant antiviral activity by mitigating EV-A71-induced cytopathic damage. Additionally, we also test the other 5-HT3 antagonists such as granisetron, tropisetron, and palonosetron. The results showed that these antagonists did not have the antiviral activity (Supplementary Figure 1A-C). To further delineate the inhibitory effects of ondansetron on viral replication kinetics and progeny virion production, quantitative reverse transcription PCR (qRT-PCR) and plaque-forming unit (PFU) assays were performed. Treatment with ondansetron resulted in a dose-dependent suppression of viral RNA replication (Figs. 1C) and a concomitant reduction in infectious viral particle yields (Figs. 1D).Fig. 1Molecular structure of ondansetron and its antiviral effect against EV-A71 in vitro. (A) Chemical structures of ondansetron. (B) Dose-dependent antiviral efficacy of ondansetron against EV-A71 in rhabdomyosarcoma (RD) cells. Cells were infected with the EV-A71 H strain (100 × TCID₅₀) and treated with serial dilutions of the compound. At 72 h post-infection (hpi), cell viability was quantified using the CellTiter-Glo assay to determine the half-maximal effective concentration (EC₅₀) and half-maximal cytotoxic concentration (CC₅₀). Selectivity indices (SI = CC₅₀/EC₅₀) were calculated as >48.63 (ondansetron). (C-D) Suppression of viral replication and progeny virion production. RD cells were infected with EV-A71 (MOI = 0.001 PFU/mL) and treated with modulators. Viral RNA levels in cell lysates were quantified by qRT-PCR at 36hpi (C), while infectious viral particles in supernatants were assessed via plaque-forming unit (PFU) assays (D). Data represent mean ± SD of triplicate experiments. Statistical significance was analyzed by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).Fig 1 dummy alt text Molecular structure of ondansetron and its antiviral effect against EV-A71 in vitro. (A) Chemical structures of ondansetron. (B) Dose-dependent antiviral efficacy of ondansetron against EV-A71 in rhabdomyosarcoma (RD) cells. Cells were infected with the EV-A71 H strain (100 × TCID₅₀) and treated with serial dilutions of the compound. At 72 h post-infection (hpi), cell viability was quantified using the CellTiter-Glo assay to determine the half-maximal effective concentration (EC₅₀) and half-maximal cytotoxic concentration (CC₅₀). Selectivity indices (SI = CC₅₀/EC₅₀) were calculated as >48.63 (ondansetron). (C-D) Suppression of viral replication and progeny virion production. RD cells were infected with EV-A71 (MOI = 0.001 PFU/mL) and treated with modulators. Viral RNA levels in cell lysates were quantified by qRT-PCR at 36hpi (C), while infectious viral particles in supernatants were assessed via plaque-forming unit (PFU) assays (D). Data represent mean ± SD of triplicate experiments. Statistical significance was analyzed by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001). Ondansetron reduces the production of EV-A71 virus protein To investigate the inhibitory effects of ondansetron on EV-A71 viral protein synthesis, viral capsid protein VP1 expression was analyzed via immunofluorescence staining and Western blot. Immunofluorescence imaging demonstrated that treatment with the ondansetron markedly suppressed VP1 protein production (Fig. 2A). Western blot analysis further corroborated this finding, revealing a dose-dependent attenuation of VP1 protein levels following ondansetron treatment (Fig. 2B). Collectively, these results indicate that ondansetron significantly inhibits EV-A71 viral protein expression by reducing VP1 synthesis in a concentration-dependent manner. Besides, we also detected the expression of 5-HTR3A in RD cells. It turned out that RD cells also express this protein. To figure out whether ondansetron exerted it antiviral effects dependent on 5-HT3 receptor, we knockdown the expression of 5-HTR3A in RD cells and then infected cells with EV-A71. By detected the expression of viral capsid VP1, we found that knockdown of 5-HTR3A did not affect the VP1 synthesis. It seemed that ondansetron exerted it antiviral activity independent on 5-HTR3A (Supplementary Figure 1D).Fig. 2Effects of Ondansetron on EV-A71 VP1 Expression: Immunofluorescence and Immunoblot Analysis. (A) RD cells were inoculated with EV-A71 (MOI = 0.001 PFU/cell) and concomitantly treated with ondansetron. Following 48 h post-infection (h.p.i.), cells were fixed for immunofluorescence analysis. Intracellular VP1 proteins were immunolabeled with mouse anti-EV-A71 VP1 monoclonal antibody (12D7; green fluorescence), while nuclei were counterstained with Hoechst 33,342 (blue fluorescence). Representative confocal microscopy images are shown (scale bar: 200 μm). (B) EV-A71-infected RD cells (MOI = 0.001 PFU/cell) were pharmacologically treated with ondansetron. Cellular lysates were harvested at 36 h.p.i. and analyzed by SDS-PAGE followed by immunoblotting using anti-VP1 antibodies (12D7). α-Tubulin was employed as a loading control.Fig 2 dummy alt text Effects of Ondansetron on EV-A71 VP1 Expression: Immunofluorescence and Immunoblot Analysis. (A) RD cells were inoculated with EV-A71 (MOI = 0.001 PFU/cell) and concomitantly treated with ondansetron. Following 48 h post-infection (h.p.i.), cells were fixed for immunofluorescence analysis. Intracellular VP1 proteins were immunolabeled with mouse anti-EV-A71 VP1 monoclonal antibody (12D7; green fluorescence), while nuclei were counterstained with Hoechst 33,342 (blue fluorescence). Representative confocal microscopy images are shown (scale bar: 200 μm). (B) EV-A71-infected RD cells (MOI = 0.001 PFU/cell) were pharmacologically treated with ondansetron. Cellular lysates were harvested at 36 h.p.i. and analyzed by SDS-PAGE followed by immunoblotting using anti-VP1 antibodies (12D7). α-Tubulin was employed as a loading control. Ondansetron acts at the pre-infection stage of EV-A71 infection To elucidate the specific phase of EV-A71 replication targeted by ondansetron, a time-of-addition pharmacological assay was performed. The compound was introduced into cell culture systems at precisely defined intervals relative to viral inoculation, as illustrated in Fig. 3A. NITD008, a pharmacologically validated flavivirus inhibitor with documented anti-EV-A71 activity (Shang et al., 2014; Lo et al., 2016; Westerterp et al., 2014), was used as the positive control. Quantitative real-time PCR analysis revealed significant suppression of viral RNA synthesis by ondansetron during Stages I and II, indicating potent inhibitory effects on viral pre-adsorption, cellular attachment, and subsequent internalization processes (Fig. 3B). To further explore the specific viral entry stage that ondansetron primarily inhibited, we performed the viral attachment and viral internalization experiment. The results showed that ondansetron was able to inhibit the viral attachment stage, while had few effect on viral internalization (Fig. 3C-D). These findings provide mechanistic evidence that ondansetron predominantly disrupts early-stage infection events, especially for viral attachment.Fig. 3Ondansetron Specifically Inhibits the Pre-entry Phase of EV-A71 Infection. (A) Temporal pharmacological intervention protocol. Schematic representation of compound administration regimens relative to viral infection timeline. (B) Intracellular viral RNA quantification. EV-A71-infected RD cells were subjected to experimental treatments following the temporal protocol in Panel A. Viral RNA was isolated at 12 h post-treatment and quantified by quantitative reverse transcription PCR (qRT-PCR). (C). In virus attachment assay, EV-A71 virus particles were pre-incubated with 0.1% DMSO vehicle control or Ondansetron (30 μM) and used to infect RD cells at M.O.I of 0.01 at 4 °C. After one hour, used DMEM medium to wash the cell and cultured the cell with new medium. The virus RNA was detected after 24 h. (D). In virus internalization assay, RD cells were infected with EV-A71 at M.O.I of 0.01 at 4 °C for one hour and washed the cell. Then the cell was treated with 0.1% DMSO vehicle control or Ondansetron (30 μM) at 37 °C. After one hour, washed the cell and cultured for another 24 h until to detect the virus RNA copies. Data represent mean ± standard deviation (SD) from three independent biological replicates. Statistical analysis was performed using one-way ANOVA with significance thresholds: *p < 0.05, ****p < 0.0001.Fig 3 dummy alt text Ondansetron Specifically Inhibits the Pre-entry Phase of EV-A71 Infection. (A) Temporal pharmacological intervention protocol. Schematic representation of compound administration regimens relative to viral infection timeline. (B) Intracellular viral RNA quantification. EV-A71-infected RD cells were subjected to experimental treatments following the temporal protocol in Panel A. Viral RNA was isolated at 12 h post-treatment and quantified by quantitative reverse transcription PCR (qRT-PCR). (C). In virus attachment assay, EV-A71 virus particles were pre-incubated with 0.1% DMSO vehicle control or Ondansetron (30 μM) and used to infect RD cells at M.O.I of 0.01 at 4 °C. After one hour, used DMEM medium to wash the cell and cultured the cell with new medium. The virus RNA was detected after 24 h. (D). In virus internalization assay, RD cells were infected with EV-A71 at M.O.I of 0.01 at 4 °C for one hour and washed the cell. Then the cell was treated with 0.1% DMSO vehicle control or Ondansetron (30 μM) at 37 °C. After one hour, washed the cell and cultured for another 24 h until to detect the virus RNA copies. Data represent mean ± standard deviation (SD) from three independent biological replicates. Statistical analysis was performed using one-way ANOVA with significance thresholds: *p < 0.05, ****p < 0.0001. Ondansetron confers protection in neonatal ICR mice against lethal EV-A71 challenge and reduce tissue viral loads To evaluate the in vivo therapeutic efficacy of ondansetron against EV-A71 infection, we employed a lethal 1-day-old ICR suckling mouse model (Deng et al., 2014). Mice were intraperitoneally (i.p.) infected with 10⁶ plaque-forming units (PFU) of EV-A71 virus (H strain), followed by i.p. administration of varying concentrations of ondansetron (1.5, 0.37mg/kg) for six consecutive days. Treatment with ondansetron at 1.5mg/kg yielded a survival rate of 70% (Fig. 4A). Body weight and survival rates were monitored up to 21 days post-infection (d.p.i.) (Fig. 4B). And treatment with ondansetron at 1.5mg/kg reduces the clinical scores, indicating an alleviation of EV-A71 infection-induced clinical symptoms (Fig. 4C). These results collectively demonstrate that ondansetron exhibits significant in vivo antiviral activity against EV-A71 infection.Fig. 4In vivo antiviral efficacy of ondansetron against EV-A71 infection. (A) Survival and Bodyweight Assessment: Neonatal ICR mice (1-day-old, n = 3 experimental groups) were intraperitoneally (i.p.) inoculated with 10⁶ plaque-forming units (PFU) of EV-A71 (H strain). Subsequently, mice received daily i.p. administration of ondansetron or vehicle control at specified doses for six consecutive days. Survival rates (A), body weight dynamics (B) and clinical score were recorded daily until 21 days or 14 days in (C) post-infection (d.p.i.). Data in B was expressed as mean ± standard deviation (SD). Survival curve was analyzed by log-rank test. *p < 0.05, **p < 0.01, ****p < 0.0001. (C-E) Tissue-Specific Viral Load Analysis: Neonatal mice (n = 2 groups) were pretreated with ondansetron (1.5mg/kg) via i.p. injection at 12-hour intervals for three days, commencing 24 h prior to challenge with 10⁶ PFU of EV-A71 (H strain). Post-euthanasia, tissue samples (brain: D; hind limp muscle: E; lung: F; liver: G; spleen: H) were harvested for quantification of viral RNA copy numbers using quantitative reverse transcription PCR (qRT-PCR). Data represent mean ± SD. Statistical significance was determined by unpaired two-tailed Student's t-test. *p < 0.05, **p < 0.01, ****p < 0.0001.Fig 4 dummy alt text In vivo antiviral efficacy of ondansetron against EV-A71 infection. (A) Survival and Bodyweight Assessment: Neonatal ICR mice (1-day-old, n = 3 experimental groups) were intraperitoneally (i.p.) inoculated with 10⁶ plaque-forming units (PFU) of EV-A71 (H strain). Subsequently, mice received daily i.p. administration of ondansetron or vehicle control at specified doses for six consecutive days. Survival rates (A), body weight dynamics (B) and clinical score were recorded daily until 21 days or 14 days in (C) post-infection (d.p.i.). Data in B was expressed as mean ± standard deviation (SD). Survival curve was analyzed by log-rank test. *p < 0.05, **p < 0.01, ****p < 0.0001. (C-E) Tissue-Specific Viral Load Analysis: Neonatal mice (n = 2 groups) were pretreated with ondansetron (1.5mg/kg) via i.p. injection at 12-hour intervals for three days, commencing 24 h prior to challenge with 10⁶ PFU of EV-A71 (H strain). Post-euthanasia, tissue samples (brain: D; hind limp muscle: E; lung: F; liver: G; spleen: H) were harvested for quantification of viral RNA copy numbers using quantitative reverse transcription PCR (qRT-PCR). Data represent mean ± SD. Statistical significance was determined by unpaired two-tailed Student's t-test. *p < 0.05, **p < 0.01, ****p < 0.0001. To further explore the antiviral effects of ondansetron in vivo, we quantified viral loads in various tissues of EV-A71-infected mice. Mice pretreated with ondansetron (1.5mg/kg) through twice-daily i.p. injections for three consecutive days, starting one day prior to EV-A71 infection (10⁵ PFU of H strain), were euthanized for tissue collection. Samples from the brain, hind limp muscle, lung, liver, and spleen were obtained for viral RNA quantification via quantitative reverse transcription PCR (qRT-PCR). As shown in (Fig. 4D-H), treatment with ondansetron significantly reduced viral loads across all tested tissues. These findings indicate that ondansetron effectively inhibits EV-A71 viral replication in vivo. Cholesterol-related homeostasis played a critical role in EV-A71 pathogenesis To elucidate the molecular mechanisms underlying the antiviral effect of ondansetron, we performed transcriptomic profiling of RD cells at 24 h post-infection (hpi) with EV-A71 under ondansetron-treated and untreated conditions. A Venn diagram analysis was conducted to identify overlapping differentially expressed genes (DEGs) in the comparisons of “ondansetron + EV-A71 vs. EV-A71” and “ondansetron + RD vs. RD,” revealing 23 shared DEGs (Fig. 5A). A minus-versus-add (MA) plot was employed to visualize the overall transcriptional changes induced by ondansetron treatment (Fig. 5B). Compared with the EV-A71 group, the ondansetron + EV-A71 group exhibited 64 upregulated and 72 downregulated DEGs (Fig. 5C).Fig. 5Cholesterol-related homeostasis is a critical determinant of EV-A71 pathogenesis. RD cells were inoculated into 12-well plates at 4 × 10⁵ cells/well and cultured overnight. Subsequently, cells were infected with 0.001 MOI of EV-A71 with the presence of 30 μM of ondansetron. At 24hpi, cells were harvested to extract total RNA and subjected to transcriptome analysis. (A). The common and unique differentially expressed genes were identified by a Venn diagram. (B). Minus-versus-add plot identified the complex upregulation and downregulation. (C). The number of differentially expressed genes (DEGs). Top enriched GO annotation analysis (D) and KEGG enrichment analysis (E) for differentially expressed genes that were upregulated by EV-A71 infection and restored by ondansetron treatment. (F). The heatmap of key DEGs related to EV-A71 infection and ondansetron intervention were visualized. The color shows the fold change of detected genes. (G). The relative expression of ABCA1, ABCG1 and HMGCS1genes were detected by RT-qPCR. (H). The RD cell was treated with EV-A71 or EV-A71 plus ondansetron (MOI: 0.001, ondansetron 30 μM) and the cell cholesterol was detected by Amplex Red Cholesterol and Cholesteryl Ester Assay Kit. (I). The RD cell were pre-treated with cholesterol–methyl-β-cyclodextrin complex (50μg/mL) and then infected with EV-A71 (MOI: 0.001). The virus RNA copies were detected by RT-qPCR. Data represent mean ± SD. Statistical significance was determined by unpaired two-tailed Student's t-test. *p < 0.05, **p < 0.01, ****p < 0.0001.Fig 5 dummy alt text Cholesterol-related homeostasis is a critical determinant of EV-A71 pathogenesis. RD cells were inoculated into 12-well plates at 4 × 10⁵ cells/well and cultured overnight. Subsequently, cells were infected with 0.001 MOI of EV-A71 with the presence of 30 μM of ondansetron. At 24hpi, cells were harvested to extract total RNA and subjected to transcriptome analysis. (A). The common and unique differentially expressed genes were identified by a Venn diagram. (B). Minus-versus-add plot identified the complex upregulation and downregulation. (C). The number of differentially expressed genes (DEGs). Top enriched GO annotation analysis (D) and KEGG enrichment analysis (E) for differentially expressed genes that were upregulated by EV-A71 infection and restored by ondansetron treatment. (F). The heatmap of key DEGs related to EV-A71 infection and ondansetron intervention were visualized. The color shows the fold change of detected genes. (G). The relative expression of ABCA1, ABCG1 and HMGCS1genes were detected by RT-qPCR. (H). The RD cell was treated with EV-A71 or EV-A71 plus ondansetron (MOI: 0.001, ondansetron 30 μM) and the cell cholesterol was detected by Amplex Red Cholesterol and Cholesteryl Ester Assay Kit. (I). The RD cell were pre-treated with cholesterol–methyl-β-cyclodextrin complex (50μg/mL) and then infected with EV-A71 (MOI: 0.001). The virus RNA copies were detected by RT-qPCR. Data represent mean ± SD. Statistical significance was determined by unpaired two-tailed Student's t-test. *p < 0.05, **p < 0.01, ****p < 0.0001. Gene Ontology (GO) enrichment analysis was subsequently conducted to annotate the functional categories of DEGs in the ondansetron-treated group, including molecular functions, cellular components, and biological processes (Fig. 5D). In parallel, KEGG pathway enrichment analysis identified 20 significantly enriched signaling pathways (Fig. 5E). A heatmap was generated to illustrate the expression profiles of representative DEGs (Fig. 5F). Among these genes, ABCA1 (ATP-binding cassette subfamily A member 1) and ABCG1 (ATP-binding cassette subfamily G member 1) mediate cholesterol efflux from the plasma membrane to high-density lipoprotein (HDL), thereby maintaining lipid homeostasis and membrane integrity. In contrast, HMGCS1 (3‑hydroxy‑3-methylglutaryl-CoA synthase 1) contributes to membrane stability by regulating cholesterol biosynthesis. Previous studies have demonstrated that ABCA1 and ABCG1 suppress EV-A71 infection by modulating membrane cholesterol content, whereas HMGCS1 facilitates viral entry through enhanced cholesterol synthesis (Sanders et al., 2021; Singh et al., 2024; Matsuo, 2022; Zhou et al., 2021; Navari, 2013). We next validated the expression of these three genes in RD cells. Consistently with the result of the RNA-seq data, the mRNA levels of ABCA1 and ABCG1 were elevated, while HMGCS1 was decreased (Fig. 5G). Meanwhile, the cholesterol level was also decreased in ondansetron plus EV-A71 treatment group (Fig. 5H). Furthermore, the rescue experiment showed that supplementing cholesterol–methyl-β-cyclodextrin complex partially restored the viral RNA copy numbers (Fig. 5I) . Collectively, these findings suggested that cholesterol-related homeostasis, mediated by host genes ABCA1, ABCG1 and HMGCS1, played a critical role in EV-A71 pathogenesis. Discussion EV-A71 remains a major global health concern due to its association with severe neurological complications and the lack of effective antiviral therapies. In the present study, we, for the first time, demonstrate that the clinically approved ondansetron exhibits significant antiviral activity against EV-A71 infection both in vitro and in vivo and may have potential roles in the clinical treatment of EV-A71 infection. Our findings also provide novel evidence and important preclinical experimental data supporting drug repurposing strategies and hold significant implications for the development of new clinical indications for ondansetron. Previous antiviral strategies against EV-A71 have primarily focused on targeting viral proteins or replication processes. However, virus-directed therapies are often limited by rapid viral mutation and the emergence of drug resistance. In contrast, targeting host factors required for viral infection offers a complementary strategy with potentially broader antiviral activity and a higher barrier to resistance. In this context, time-of-addition assays revealed that the inhibitory effect is most pronounced during the pre-entry phase. Further data indicate that ondansetron exerts its antiviral effects predominantly at the early stage of infection, especially for viral attachment. The transcriptomic analysis, which identified significant alterations in cholesterol metabolism-related genes, including ABCA1, ABCG1, and HMGCS1. Cholesterol is a critical component of the plasma membrane and plays an essential role in maintaining membrane fluidity and the formation of lipid rafts, which are often exploited by viruses for entry. ABCA1 and ABCG1 are key regulators of cholesterol efflux, whereas HMGCS1 is involved in cholesterol biosynthesis. Previous studies have demonstrated that modulation of membrane cholesterol can significantly affect viral entry and infectivity. In agreement with these findings, our results suggest that ondansetron disrupts cholesterol homeostasis, thereby altering membrane properties and impairing EV-A71 attachment. Importantly, our in vivo data showed the significantly improved survival in EV-A71-infected neonatal mice and reduced viral loads among multiple tissues by ondansetron treatment. These findings highlight the translational potential of ondansetron as a therapeutic candidate, particularly given its well-established clinical safety profile. Despite these promising findings, several limitations and unresolved issues remain in this study. Firstly, we only investigated the antiviral effects of ondansetron as a 5-HT3 receptor inhibitor. Currently, multiple 5-HT3 receptor antagonists have been identified, including granisetron, tropisetron, and palonosetron (Rojas et al., 2010; Owino and Chu, 2019). While our data showed that these antagonists could not inhibit EV-A71 infection. Besides, knockdown of 5-HTR3A did not affect the antiviral activity of ondansetron. These results indicated that the antiviral activity of ondansetron might be an off-target effect. Or in another word, it is a kind of drug repurposing. Drug repurposing has emerged as a highly attractive strategy to shorten development timelines and mitigate safety risks. Andrographolide, which inhibits EV-D68 maturation in acidic endosomes, or Pirlindole, which suppresses CV-B3 replication has demonstrated significant promise. Furthermore, natural products, particularly flavonoids like Quercetin and Apigenin, offer multi-target potential by blocking viral attachment or inhibiting IRES-mediated translation [36]. In our research, the specific protein target that ondansetron interacts with is still unclear and it needs more experiments to explore. Secondly, we find that ondansetron can affect the expression of cholesterol metabolism genes ABCA1, ABCG1, and HMGCS1, thereby decrease the cell cholesterol level and inhibit EV-A71 attachment. However, the precise molecular mechanisms of the cell membrane cholesterol homeostasis and its interaction model with ondansetron in viral attachment remain to be further elucidated. Finally, although ondansetron is an approved drug, its pharmacokinetic optimization, dose–response characteristics, and clinical efficacy against EV-A71 infection have not yet been established, and further clinical studies are needed. Nonetheless, our work is the first to reveal that the ondansetron exhibits significant inhibitory effects on EV-A71 infection both in vitro and in vivo in preclinical studies. This provides a potential therapeutic option for the clinical treatment of EV-A71 infection and identifies important potential host targets for developing antivirals against EV-A71. Conclusion This study demonstrates that ondansetron exhibits significant antiviral activity in both in vitro and in vivo models of EV-A71 infection. Mechanistically, ondansetron may exert its antiviral effect by modulating cholesterol metabolism-related genes (ABCA1, ABCG1, HMGCS1), thereby affecting the stability of the cell cholesterol homeostasis, which in turn influences viral attachment and inhibit virus entry. Ethics statement All animal procedures were approved by the Institutional Animal Care and Use Committee of the Beijing Institute of Pharmacology and Toxicology. Infectious virus experiments were conducted under Biosafety Level 2 (BSL-2) containment for in vitro studies and Animal Biosafety Level 2 (ABSL-2) facilities for in vivo work. Consent for publication Not applicable. Funding This research was funded by the National Natural Science Foundation of China (NSFC, grants 82,574,325, 82,404,707.) CRediT authorship contribution statement Zhenyang Li: Writing – original draft, Methodology, Investigation, Funding acquisition, Conceptualization. Jianqiao Rui: Writing – original draft, Methodology, Investigation, Conceptualization. Jiazheng Li: Writing – original draft, Methodology, Investigation. Sichen Ren: Writing – review & editing. Yan Luo: Writing – review & editing. Weiyan Zhu: Writing – review & editing. Huimin Tao: Validation. Mingzhu Guo: Validation. Qingsong Dai: Validation. Wan Peng: Validation. Siqi Li: Validation. Xiaojia Guo: Validation. Wei Li: Validation. Jingjing Yang: Supervision, Funding acquisition, Conceptualization. Ruiyuan Cao: Supervision, Funding acquisition, Conceptualization. Wu Zhong: Supervision, Funding acquisition, Conceptualization. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.